Cooper Jeffrey H 4

4 · Sierra Oncology, Inc. · Filed Jul 1, 2022

Form 4

Period: 2022-07-01

Director

Transactions

Disposition to Issuer
Stock Option (right to buy)
2022-07-01−625→ 0 total
Exercise: $45.20Exp: 2027-06-13→ Common Stock (625 underlying)
Disposition to Issuer
Stock Option (right to buy)
2022-07-01−625→ 0 total
Exercise: $130.80Exp: 2028-06-12→ Common Stock (625 underlying)
Disposition to Issuer
Stock Option (right to buy)
2022-07-01−18,061→ 0 total
Exercise: $13.98Exp: 2030-06-09→ Common Stock (18,061 underlying)
Disposition to Issuer
Stock Option (right to buy)
2022-07-01−1,941→ 0 total
Exercise: $82.40Exp: 2026-06-09→ Common Stock (1,941 underlying)
Disposition to Issuer
Stock Option (right to buy)
2022-07-01−750→ 0 total
Exercise: $26.40Exp: 2029-06-11→ Common Stock (750 underlying)
Disposition to Issuer
Stock Option (right to buy)
2022-07-01−6,000→ 0 total
Exercise: $18.11Exp: 2031-06-08→ Common Stock (6,000 underlying)

Footnotes (8)

[F1]The option fully vested on June 9, 2017.
[F2]Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger.
[F3]The option fully vested on June 13, 2018.
[F4]Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price.
[F5]The option fully vested on June 12, 2019.
[F6]The option fully vested on June 11, 2020.
[F7]The option fully vested on June 9, 2021.
[F8]The option fully vested on June 8, 2022.

Documents

1 file